Baicalin–Chlorogenic Acid Composition for Endogenous Hyaluronic Acid Synthesis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing solutions for increasing hyaluronic acid (HA) content in the skin either rely on impractical administration methods or do not effectively stimulate natural HA synthesis, leading to dependence on external compositions.

Innovation Solution

A composition comprising baicalin or its derivatives, optionally combined with chlorogenic acid or its derivatives, is used to stimulate cellular synthesis of hyaluronic acid and enhance immunocutaneous responses, addressing both HA synthesis and skin health.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If subcutaneous or intradermal injection of hyaluronic acid is used, then HA content in skin is increased, but administration becomes impractical and requires skilled personnel

Engineering Contradiction:
ImproveHA content in skinVSAvoidadministration method
Core Design Contradiction:
Quantity of substanceVSEase of operation

Solution Approach 1:

The patent replaces the mechanical injection system (needles, syringes, skilled personnel) with a topical chemical system. The composition uses small molecules (resveratrol, quercetin, kaempferol, myricetin) that can penetrate skin barriers and stimulate endogenous HA synthesis through biochemical pathways, eliminating the need for invasive mechanical administration.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention enables the skin to produce its own hyaluronic acid through stimulation by the topical composition. Instead of externally supplying HA that requires injection, the active ingredients trigger fibroblasts and other skin cells to synthesize HA autonomously, making the system self-sufficient and eliminating dependence on repeated professional administrations.

Inventive Principle:
Principle #25Self-service

2Quantity of substance

If topical compositions directly supply HA to enrich skin, then HA content is increased, but natural HA synthesis is not stimulated leading to dependence on external compositions

Engineering Contradiction:
ImproveHA content in skinVSAvoidnatural synthesis capability
Core Design Contradiction:
Quantity of substanceVSAdaptability or versatility

Solution Approach 1:

The composition transforms the skin from a passive recipient of external HA to an active producer. The flavonoids and polyphenols stimulate endogenous synthesis pathways in fibroblasts, allowing the skin to regenerate its own HA stores independently, thereby eliminating long-term dependence on external supplementation.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

Instead of changing the physical form of HA delivery (from injection to topical), the invention changes the fundamental parameter from direct HA supply to stimulation of HA synthesis. The active ingredients modify cellular metabolism and gene expression to increase endogenous production, fundamentally altering how HA is obtained rather than merely changing the delivery route.

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If topical compositions are used to increase HA content, then HA levels are improved, but the method lacks effectiveness in stimulating natural synthesis

Engineering Contradiction:
ImproveHA content in skinVSAvoidnatural HA synthesis rate
Core Design Contradiction:
Quantity of substanceVSProductivity

Solution Approach 1:

The flavonoids and polyphenols act as intermediary molecules that bridge the gap between topical application and endogenous HA production. These small, skin-penetrating compounds serve as signaling mediators that activate cellular pathways (such as TGF-beta and other growth factor pathways) to stimulate fibroblast activity and HA synthesis, rather than directly supplying HA or relying on large molecular weight HA topically.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS20250268860A1Composition for use in the cutaneous synthesis of hyaluronic acid, in an immuno-cutaneous response and to improve skin
Publication Date: 2025.08.28 SHIKOKU RAILWAY COMPANY
  • US20250268860A1 patent drawing
  • US20250268860A1 patent drawing
  • US20250268860A1 patent drawing

AI summary

A composition comprising baicalin or a derivative thereof, more particularly in combination with chlorogenic acid or a derivative thereof, as well as the cosmetic use of such a composition and its medical applications.